Meeting Agenda

• Call to Order/Roll Call
• Welcome and Introductions
• Overview of Task Force Charge
• Summary of Draft USCDI v2
• Task/Charge Priorities and Breakdown
• Timeline and Meeting Schedule
• Public Comment
• Adjourn
# Task Force Roster

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Lane (Co-Chair)</td>
<td>Sutter Health</td>
</tr>
<tr>
<td>Terry O’Malley (Co-Chair)</td>
<td>Individual</td>
</tr>
<tr>
<td>Ricky Bloomfield</td>
<td>Apple</td>
</tr>
<tr>
<td>Hans Buitendijk</td>
<td>Cerner</td>
</tr>
<tr>
<td>Valerie Grey</td>
<td>New York eHealth Collaborative</td>
</tr>
<tr>
<td>Jim Jirjis</td>
<td>HCA Healthcare</td>
</tr>
<tr>
<td>Ken Kawamoto</td>
<td>University of Utah Health</td>
</tr>
<tr>
<td>Leslie Kelly Hall</td>
<td>Engaging Patient Strategy</td>
</tr>
<tr>
<td>Leslie Lenert</td>
<td>Medical University of South Carolina</td>
</tr>
<tr>
<td>Clement McDonald</td>
<td>National Library of Medicine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Miri</td>
<td>University of Texas at Austin</td>
</tr>
<tr>
<td>Brett Oliver</td>
<td>Baptist Health</td>
</tr>
<tr>
<td>Mark Savage</td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>Michelle Schreiber</td>
<td>CMS</td>
</tr>
<tr>
<td>Sasha TerMaat</td>
<td>Epic</td>
</tr>
<tr>
<td>Andrew Truscott</td>
<td>Accenture</td>
</tr>
<tr>
<td>Sheryl Turney</td>
<td>Anthem, Inc.</td>
</tr>
<tr>
<td>Dan Vreeman</td>
<td>RTI International</td>
</tr>
<tr>
<td>Denise Webb</td>
<td>Indiana Hemophilia and Thrombosis Center</td>
</tr>
</tbody>
</table>
Task Force Charge

Overarching charge:

Review and feedback on the Draft USCDI Version 2 content and process

Specific charges:

• Evaluate Draft USCDI v2 and provide HITAC with recommendations for:
  • Data classes and elements from USCDI v1 including applicable standards version updates
  • New data classes and elements from Draft USCDI v2 including applicable standards
  • Level 2 data classes and elements not included in Draft USCDI v2
  Due: April 15, 2021

• Evaluate the USCDI expansion process and provide HITAC with recommendations for:
  • ONDEC submission system improvements
  • Evaluation criteria and process used to assign levels to submitted data classes and elements
  • Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2
  Due: September 9, 2021

• Recommend prioritization areas for USCDI version 3 submission cycle
  Due: September 9, 2021
# USCDI ONDEC Submissions – Version 2

<table>
<thead>
<tr>
<th>Level Assignments</th>
<th>Data Elements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 2</td>
<td>109</td>
</tr>
<tr>
<td>Level 1</td>
<td>55</td>
</tr>
<tr>
<td>Comment Level</td>
<td>140</td>
</tr>
<tr>
<td>Total Data Elements Submitted</td>
<td>664*</td>
</tr>
</tbody>
</table>

*Includes Merged/Duplicated data elements*
# Submission Evaluation Criteria

<table>
<thead>
<tr>
<th>CRITERIA</th>
<th>COMMENT LEVEL</th>
<th>LEVEL 1</th>
<th>LEVEL 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maturity-Current Standards</td>
<td>May be represented by terminology standard or element of Standards Development Organization (SDO) balloted technical specification</td>
<td>Must be represented using terminology standard or element of SDO-balloted technical specification</td>
<td>Must be represented using terminology standard or element of SDO-balloted technical specification</td>
</tr>
<tr>
<td>Maturity-Current Use</td>
<td>Limited test environments, or pilots</td>
<td>Limited production environments, 1 or 2 different systems</td>
<td>At scale in production environments more than 2 different systems</td>
</tr>
<tr>
<td>Maturity-Current Exchange</td>
<td>Limited exchange with external organizations, on same or different EHR/HIT systems</td>
<td>Exchanged between 2 or 3 organizations with different EHR/HIT systems</td>
<td>Exchanged between 4 or more organizations with different EHR/HIT systems</td>
</tr>
<tr>
<td>Use Cases- # Stakeholders Impacted</td>
<td>Used by few stakeholders, or for narrowly defined conditions or events.</td>
<td>Pertinent to many, but not most patients, providers or events requiring its use</td>
<td>Pertains to majority of patients, providers or events requiring its use</td>
</tr>
</tbody>
</table>
Draft USCDI version 2
Update Process

ONC Prioritization criteria for Level 2 data elements

- Significant gaps in USCDI v1 concepts
- Supported by existing ONC Certification
- Modest technical standards development
- Modest aggregate lift for vendor development and implementation, esp. during pandemic
Draft USCDI v2

Allergies and Intolerances
- Substance (Medication)
- Substance (Drug Class)
- Reaction

Assessment and Plan of Treatment
- Assessment and Plan of Treatment

Care Team Members
- Care Team Members
- Provider Name
- Provider Identifier

Clinical Notes
- Consultation Note
- Discharge Summary Note
- History & Physical
- Procedure Note
- Progress Note

Diagnostic Imaging
- Diagnostic Imaging Order
- Diagnostic Imaging Report
- Diagnostic Imaging Narrative

Encounter Information
- Encounter Type
- Encounter Diagnosis
- Encounter Time

Goals
- Patient Goals

Health Concerns
- Health Concerns

Immunizations
- Immunizations

Laboratory
- Tests
- Values/Results
- Laboratory Report Narrative
- Pathology Report Narrative

Medications
- Medications

Patient Demographics
- First Name
- Last Name
- Previous Name
- Middle Name (incl. middle initial)
- Suffix
- Birth Sex
- Date of Birth
- Race
- Ethnicity
- Preferred Language
- Current Address
- Previous Address
- Phone Number
- Phone Number Type
- Email Address

Problems
- Problems
- Date of Diagnosis
- Date of Resolution

Procedures
- Procedures

Provenance
- Author Time Stamp
- Author Organization

Smoking Status
- Smoking Status

Unique Device Identifier(s)
for a Patient’s Implantable Device(s)
- Unique Device Identifier(s)
for a Patient’s Implantable Device(s)

Vital Signs
- Diastolic Blood Pressure
- Systolic Blood Pressure
- Body Height
- Body Weight
- Heart Rate
- Respiratory Rate
- Body Temperature
- Pulse Oximetry
- Inhaled Oxygen Concentration
- BMI Percentile (2-20 Years)
- Weight-for-length Percentile (Birth-36 Months)
- Occipital-frontal Head Circumference Percentile (Birth-36 Months)

Key
- New Data Class or Element
- Data Element reclassified
USCDI Version Update Process

2020

Submission & Review Period - v2
- OCN v2 Draft Prep
- HITAC v2 Public Comment v2

USCDI v1 Final
October

USCDI v2 Draft
January

2021

Submission & Review Period - v3
- OCN v2 Review/Approval

USCDI v2 Final
April

Considered for 2021 SVAP

2022

Submission & Review Period - v4
- OCN v3 Draft Prep
- HITAC v3 Public Comment v3

USCDI v3 Draft
October

USCDI v3 Final
January

Considered for 2022 SVAP

April

July
Task/Charge Priorities and Breakdown

Overarching charge:

Review and feedback on the Draft USCDI Version 2 content and process

Specific charges:

- **Evaluate Draft USCDI v2 and provide HITAC with recommendations for:**
  - Data classes and elements from USCDI v1 including applicable standards version updates
  - New data classes and elements from Draft USCDI v2 including applicable standards
  - Level 2 data classes and elements not included in Draft USCDI v2
  
  **Due:** April 15, 2021

- **Evaluate the USCDI expansion process and provide HITAC with recommendations for:**
  - ONDEC submission system improvements
  - Evaluation criteria and process used to assign levels to submitted data classes and elements
  - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2
  
  **Due:** September 9, 2021

- **Recommend prioritization areas for USCDI version 3 submission cycle**
  
  **Due:** September 9, 2021
Next TF Meetings

• February 9, 2021, 10:30 am - 12:00 pm ET
• February 16, 2021, 10:30 am - 12:00 pm ET
• February 23, 2021, 10:30 am - 12:00 pm ET
Public Comment

To make a comment please call:
Dial: 1-877-407-7192

(Once connected, press “*1” to speak)

All public comments will be limited to three minutes.

You may enter a comment in the “Public Comment” field below this presentation.

Or, email your public comment to onc-hitac@accelsolutionsllc.com.

Written comments will not be read at this time, but they will be delivered to members of the Task Force and made part of the Public Record.
Questions?
Meeting Adjourned